In a phase I trial, patients suffering from advanced or metastatic NSCLC, colorectal cancer, or pancreatic adenocarcinoma, and having KRAS mutations, are being enrolled to determine the efficacy of mRNA-5671 with or without pembrolizumab (NCT03948763). Here, KRAS is linked to colorectal cancer.